For Healthcare Professionals

A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin

clipboard-pencil

About the study

The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Have a clinical diagnosis of T2D based on the World Health Organization classification or other locally applicable diagnostic standards.
  2. Have HbA1c ≥7.0% (53 mmol/mol) to ≤10.5% (91 mmol/mol) at screening.
  3. Have been on stable diabetes treatment with metformin ≥1500 milligram per day (mg/day) during the 90 days prior to screening and maintained through randomization.
  4. Are of stable body weight (±5%) for at least 90 days prior to screening and agree to not initiate an intensive diet or exercise program during the study with the intent of reducing body weight, other than the lifestyle and/or dietary measures for diabetes treatment.
  5. Have a body mass index (BMI) ≥23.0 kilogram/square meter (kg/m²) at screening.

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Have Type 1 Diabetes (T1D)
  2. Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  3. Have an estimated glomerular filtration rate (eGFR) <45 milliliter per minute (mL/min)/1.73 square meter (m2)
  4. Have acute or chronic hepatitis
  5. Have had chronic or acute pancreatitis any time.
  6. Have been treated with any antihyperglycemic medication (other than metformin) within the 90 days prior to screening.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 1-317-615-4559Email iconEmail Study Center

Study Details


Contition

Type 2 Diabetes

Age

18+

Phase

PHASE3

Participants Needed

888

Est. Completion Date

Oct 27, 2025

Treatment Type

INTERVENTIONAL


Sponsor

Eli Lilly and Company

ClinicalTrials.gov NCT Identifier

NCT06192108

Study Number

J2A-MC-GZGV

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.